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Visualization of poly(ADP-ribose) bound to PARG
reveals inherent balance between exo- and
endo-glycohydrolase activities
Eva Barkauskaite1,*, Amy Brassington2,*, Edwin S. Tan3, Jim Warwicker2, Mark S. Dunstan2, Benito Banos1,
Pierre Laﬁte4, Marijan Ahel5, Timothy J. Mitchison3, Ivan Ahel1,6 & David Leys2
Poly-ADP-ribosylation is a post-translational modiﬁcation that regulates processes involved
in genome stability. Breakdown of the poly(ADP-ribose) (PAR) polymer is catalysed by
poly(ADP-ribose) glycohydrolase (PARG), whose endo-glycohydrolase activity generates PAR
fragments. Here we present the crystal structure of PARG incorporating the PAR substrate.
The two terminal ADP-ribose units of the polymeric substrate are bound in exo-mode.
Biochemical and modelling studies reveal that PARG acts predominantly as an exo-glycohy-
drolase. This preference is linked to Phe902 (human numbering), which is responsible for
low-afﬁnity binding of the substrate in endo-mode. Our data reveal the mechanism of poly-
ADP-ribosylation reversal, with ADP-ribose as the dominant product, and suggest that the
release of apoptotic PAR fragments occurs at unusual PAR/PARG ratios.
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oly-ADP-ribosylation is a reversible post-translational
modiﬁcation that regulates a variety of cellular functions
involved in genome stability1–4. Poly(ADP-ribose) (PAR)
synthesis is achieved by poly(ADP-ribose) polymerases (PARPs),
which, by using NAD as substrate, link repeating ADP-ribose
units via unique O-glycosidic ribose–ribose bonds5. Efﬁcient and
timely breakdown of the PAR polymer is catalysed by a PAR
glycohydrolase (PARG), and PARG depletion results in
embryonic lethality in mouse models, as well as increased
radiosensitivity and chemosensitivity in cells, making PARG an
attractive therapeutic target6–8. The complex chemical nature of
the poly(ADP-ribose) polymer has limited the understanding of
the structure and recognition of this signalling molecule.
Recent structure determination of PARG from bacterial,
protozoan and mammalian sources9–12 revealed that these
enzymes essentially consist of a macrodomain ADP-ribose-
binding module13, elaborated upon through insertion of the
highly conserved and PARG-speciﬁc catalytic loop (containing
the key catalytic residues), and both N- and C-terminal
extensions. Canonical eukaryotic PARGs are more complex
when compared with their prokaryotic counterparts. In terms of
size, canonical PARGs are bigger and contain a signiﬁcantly
larger accessory domain to the aforementioned, essential
substrate-binding macrodomain (Supplementary Fig. S1).
Furthermore, the bacterial type PARGs have recently been
shown to act solely in an exo-glycohydrolase mode9, whereas
canonical PARGs have been reported to exhibit both endo- and
exo-glycohydrolase activities14. PARG is unable to cleave the ester
bond linking the proximal ADP-ribose unit directly to proteins9.
Although the enzymatic activity that catalyses this step of PAR
catabolism has been detected in mammalian cell extracts 30 years
ago, the proteins responsible remained unknown until very
recently15–18. The deﬁciency in the proteins demodifying
mono(ADP-ribosyl)ated PARP substrates in cells leads to a
severe neurodegeneration disease in humans16,19.
To provide detailed understanding of the inherent endo- and
exo-glycohydrolase activities of canonical PARGs, we set out to
determine the structure of an inactive PARG in complex with the
PAR substrate. Crystal structure determination of the E256Q
Tetrahymena thermophila PARG in complex with PAR fragments
surprisingly yielded only exo-glycohydrolase-mode complexes.
The inherent preference for exo- (as opposed to endo-) binding is
linked to the presence of the conserved residue Phe902 (human
numbering), and this is conﬁrmed by detailed studies of product
proﬁles for canonical PARGs. We conclude that, in contrast to
bacterial PARG, canonical PARGs can act as endo-glycohydro-
lases. The balance between exo- and endo-activity is likely to be a
function of the PARG/PAR ratio, offering the possibility that
apoptotic PAR fragments are only formed at unusual PARG/PAR
ratios.
Results
Crystal structure of the inactive TTPARG with PAR.T o
understand poly-ADP-ribose binding by canonical PARGs, we
prepared homogenous PAR fragments. PAR was prepared by
enzymatic synthesis using the activity of PARP Tankyrase1 as
described20, which assures the production of biologically relevant
polymers. The PAR fragments were resolved by anionic
chromatography at single-nucleotide resolution, providing
sufﬁcient amounts of homogenous PAR fragments of deﬁned
lengths for the envisioned structural studies (Supplementary Fig.
S2). Size identity of PAR fragments was conﬁrmed by mass
spectrometry.
The inactive E256Q TTPARG mutant was co-crystallized with
a series of deﬁned length PAR oligomers, ranging from a 6-mer
to a 16-mer fragment. Crystals were obtained in a range of
conditions, for each of the PAR polymers tested. In all cases, the
same crystal packing was observed, regardless of PAR polymer
size or mother liquor composition. No signiﬁcant difference in
the corresponding structures was observed, and we report the
highest resolution structure obtained to 1.46Å for a E256Q
TTPARG in complex with a PAR9 (PDB code 4L2H).
Compared with previously determined TTPARG structures10,
changes in the TTPARG protein structure are minor and are
probably due to the distinct crystal packing obtained for the
PARG–PAR9 complex. The bound poly-ADP-ribose can clearly
be discerned from the electron density, but only the two terminal
ADP-ribose units are visible (Fig. 1a). The terminal ADP-ribose
moiety occupies a position similar to that observed for the
product ADP-ribose molecule. The ribose–ribose O-glycosidic
linkage between both ADP-riboses is clearly visible and is
positioned in close proximity of the Gln256 side chain (Fig. 1b).
In contrast to the interactions between Asn250 and Glu255 and
the terminal ribose’, no direct interactions are observed between
protein and the n-1 ribose’. The 3-OH group of the latter is
within hydrogen bonding distance of the terminal n ribose’ 3-OH
(in turn bound by Asn240) and a water molecule (referred to as
W2). The W2 is bound by the Gly246 amide nitrogen and the n
ribose’ 2-OH group (bound to Glu255). The n-1 adenosine is
sandwiched between Val253 and water molecules that interact
with Arg164. Direct hydrogen bonding interactions between the
Leu252 amide nitrogen and the n-1 adenosine N11, as well as the
Ser297 side chain and the n-1 adenosine N10, can also be
observed. A few polar interactions occur between the protein and
the n-1 diphosphate, including the amide nitrogen backbone, and
side chain of Asn250. As a consequence, starting with the n-1 a-
phosphate towards the N-2 ADP-ribose group of the PAR chain,
electron density rapidly becomes weaker, signifying high levels of
ﬂexibility in the bound PAR from the n-1 a-phosphate onwards.
Beyond the n-1 b-phosphate, electron density is reduced to
background level, corresponding to the large crystal solvent
channel that lines the TTPARG active-site region (Supplementary
Fig. S3). The latter region is sufﬁciently large to contain the
remaining disordered PAR section.
Comparison of the TTPARG–PAR9 structure with the recently
published human PARG structure12 reveals that the majority of
PARG–PAR interactions are conserved across eukaryotic PARGs
(Supplementary Fig. S4). The few differences that are observed
are located in the vicinity of the n-1 ADP-ribose unit, providing
further evidence that this region does not signiﬁcantly contribute
to PAR binding (Fig. 2). Indeed, mutations of residues implicated
in the binding of the n-1 ADP-ribose suggested by the TTPARG–
PAR crystal structure, or, by analogy, a human PARG–PAR
model, have little to no effect on PARG catalytic activity (Fig. 2).
In contrast, mutations of residues implicated in the binding of the
n adenosine moiety in humans and TTPARGs signiﬁcantly
diminish activity, suggesting that analogous PAR binding mode
also occurs in human PARG.
PARG binds PAR in an exo-glycohydrolase binding mode. The
observed binding mode corresponds to a PARG exo-glycohy-
drolase activity, and, given the fact that previous studies suggested
potential PAR conformations corresponding to endo-glycohy-
drolase activity were compatible with canonical PARG
structures10–12, comes as a surprise. The 2-OH group of the
terminal ribose’ is indeed solvent exposed (Fig. 1a), suggesting
that a further nþ1 unit could ﬁt at the PARG surface. The crystal
packing is also such that a large solvent channel runs along the
PARG active-site surface, and is thus unlikely to inﬂuence
the observed PAR conformation (Supplementary Fig. S3). We
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TTPARG–PAR structure and compared the average architectures
of an exo-glycohydrolase and an endo-glycohydrolase binding
mode during molecular dynamics (MD) simulations (Fig. 3a).
These reveal that although binding of an additional nþ1 unit is
indeed possible, this requires a reorientation of the n ribose’ to
allow for the presence of the additional nþ1 ribose’ unit and
avoid steric clashes with conserved Phe398 (Fig. 3b). This in turn
leads to a reorientation of the n adenosine, which is no longer
able to maintain a series of polar interactions with the side chain
of Glu228 and the amide nitrogen of Ile227. In addition, a water-
mediated interaction with Lys365 and Cys396 backbone atoms is
also disrupted. The disruption of complementarity between the
PARG active site and the n adenosine provides a likely
explanation for the observed preference to bind the PAR
terminus (Table 1). Given the fact that only an exo-
glycohydrolase conformation was observed for different PAR
lengths, with the longest oligomer reaching 15 ADP-ribose units
(which contains only 1 terminal residue, compared with 13
intermediate positions), this preference can be estimated to be at
least 100-fold.
PARG acts mainly as an exo-glycohydrolase. The above obser-
vations suggest that correct positioning of the n adenosine moiety
is indeed important for PARG (exo)glycohydrolase functionality.
The mutation of Glu228 to Ala or Ile227 to Pro indeed sig-
niﬁcantly affects, but does not abolish, TTPARG activity (Fig. 2a).
N-ribose 2OH N-ribose 2OH
N-ribose 3OH
N-ribose′  3OH N-ribose′ 3OH
(N-1) ribose 3OH (N-1) ribose 3OH
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b
Figure 1 | Crystal structure of a PARG–PAR complex. (a) Stereoview of the solvent-accessible surface of PARG in grey with the bound PAR at the active-site
surface shown in atom-coloured sticks. The 2FoFc electron density corresponding to the ordered region of PAR is shown in a blue mesh (contour level 1 sigma).
(b) Stereoview of the PARG active site. Residues involved in direct contacts with the PAR ligand are shown in atom-coloured sticks. The mutated Glu256 is
shown with green rather than with light blue carbons. Hydrogen bonds between ligand and protein or structural waters are indicated by dotted lines.
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but not catalysis, but could also reﬂect that a proportion of endo-
glycohydrolase activity does occur. To further estimate the extent
of PARG endo-glycohydrolase activity, we used a mutant bac-
terial PARG to inhibit the activities of canonical PARG proteins.
Unlike eukaryotic PARGs, bacterial PARG shields the terminal n
ribose’ from solvent access and was shown to exclusively operate
as an exo-glycohydrolase9. The Glu115Gln bacterial PARG
mutant (corresponding to the Glu256Gln in TTPARG) binds to
the PARG reaction product ADP-ribose as efﬁciently as the wild-
type (WT) protein, and it was added in increasing ratios with an
aim to protect the substrate PAR termini, gradually allowing for
(any residual) endo-glycohydrolase activity only to occur.
However, complete inhibition of canonical PARG was observed
at higher Glu115Gln concentrations, suggesting that all available
PAR termini are protected from PARG exo-glycohydrolase
activity (Fig. 2b). This suggests that canonical PARG endo-
glycohydrolase activity is not comparable to exo-glycohydrolase
activity under the conditions used. Detection of PARG endo-
glycohydrolase activity has been historically challenging. To
overcome this, we developed a sensitive liquid chromatography/
mass spectrometry (LC/MS) method that allowed us to detect
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Figure 2 | PARG mutagenesis and PAR termini protection by bactPARG conﬁrms the PARG–PAR model. (a) Activity of the T. thermophila PARG
WT and mutants and the corresponding human PARG mutants. Error bars represent s.d. (n¼3) (*Po0.05; **Po0.01; ***Po0.001) obtained using
paired t-test. (b) Inhibition of glycohydrolase activity for both human and T. thermophila PARGs using PARP1-generated PAR substrate with bactPARG
Glu115Gln. (c) Distribution of exo- and endo-glycohydrolase products obtained after treatment with wt and mutant human and T. termophila PARGs,
as determined by LC/MS (see also Supplementary Fig. S6).
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long PAR chains to further increase a chance for endo-
glycohydrolitic action. In the conditions used, the PARG
reaction enriched the shorter endo products (probably owing to
the coupling with exo reaction) and ADP-ribose oligomers of
more than four repeats could not be detected (Fig. 2c). Bacterial
Glu115Gln PARG is also able to inhibit human PARG activity,
and our LC/MS data reveal a similar predisposition of the human
PARG to generating the ADP-ribose exo-glycohydrolase product,
suggesting that canonical PARG activity substrate preferences are
conserved across the eukaryotic kingdoms. We generated a
Phe398Gly mutation in TTPARG and the corresponding
Phe902Gly mutation in human PARG to remove the steric
clash that occurs with the poly(ADP-ribose) bound in the endo-
glycohydrolase mode. In comparison with the WT human and
TTPARG proteins, LC-MS analysis reveals an approximate
four- and sevenfold increase of endo-glycohydrolase products,
respectively (Fig. 2c), supporting the role of Phe398/Phe902 in
balancing the relative endo/exo-activities of canonical PARGs.
A role for both conserved glutamates in catalysis. A model of
the TTPARG–PAR Michaelis complex can be derived by posi-
tioning the Glu256 in a conformation as observed in the WT
TTPARG–ADP-ribose complex (PDB ID:4EPP). This reveals that
Glu256 is within the hydrogen bonding distance of the O-gly-
cosidic ribose–ribose bond, thus suggesting that Glu256 is
protonated. We performed pKa calculations for the free enzyme
Table 1 | Observed variation of key distances across the MD
simulations for a PARG–PAR3 model.
Distance (Å) E256Q structure
(PDB code
4L2H)
TTPARG
PAR3
exo model
TTPARG
PAR3
endo model
Y293(OH)—PAR3
(N6)
3.8 3.5±0.1 5.3±0.2
E228(OE1)—PAR3
(N6)
3.0 3.7±0.3 5.1±0.2
I227(N)—PAR3 (N1) 3.1 3.5±0.2 4.6±0.1
Average distances derived from MD simulations between protein residues and nitrogen atoms
of the PAR adenosine moiety bound in the I227/E228/Y293 pocket.
N+1
N+1 N+1
N-1
N
N endo N endo
N exo
I227
a
b
E228 E228
L226 L226 I227
Y293 Y293
Y296 Y296
F398 F398
N exo
F398
Figure 3 | Model of the PARG–PAR complex in endo-glycohydrolase mode. (a) Solvent-accessible surface of PARG in grey (the position of Phe398 is
shown in blue) with a PAR3 modelled in an endo-glycohydrolase position. Carbons belonging to the three individual ADP-ribose units are coloured
distinctly. (b) Stereoview of an overlay of the modelled endo-glycohydrolase PAR3 (colour coded as in panel a) with the observed exo-glycohydrolase
crystal structure. Residues implicated in steric hindrance with the additional Nþ1 unit are shown in VDW spheres (Phe398 and Leu226). The hydrogen
network between the N adenosine and the protein/structural water observed for the exo-glycohydrolase binding mode is shown in dotted lines.
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Glu256 are predicted to be negatively charged in the free enzyme.
Although the predicted pKa of Glu256 does not change sub-
stantially for the Glu255Ala mutant in the free enzyme, the
charge coupling between both glutamic acid residues is much
increased when the substrate is bound such that one proton is
added to the pair. As is common for tightly coupled protonations,
the precise location of the proton is more difﬁcult to predict, but
hydrogen bonding within the active site is consistent with the side
chain of Glu256 picking up a proton in the enzyme–substrate
complex. Calculations suggest that in the Glu255Ala mutant,
where the charge coupling is removed, the Glu256 pKa reverts to
a much lower value, and is less likely to pick up a proton. This
implies that Glu256 becomes protonated by W2 on PAR binding,
and establishes a clear role for Glu255 in the catalytic mechanism
that extends beyond the binding of the n ribose’ 2-OH group
(Fig. 4). The elevated pKa of Glu256 allows it to protonate the
leaving group on concomitant formation of the oxocarbenium
intermediate. The Glu256-mediated hydrolysis of this inter-
mediate can then occur either by W1 (which is within the
hydrogen bonding distance of the ribose’ C2) or by W2. Mod-
elling studies indicate that the motion of W1 is severely restricted
compared with W2, and thus it seems plausible that the latter is
responsible for PAR hydrolysis, leading to the a-ribose product.
PARG does not hydrolyse mono-ADP-ribosylated substrates.
Modelling of a glutamate linkage to the n ribose’, to mimic the
protein-PAR linkage, leads to clashes of the glutamate carboxylate
moiety with PARG Val253 and Ala370. Furthermore, the pre-
sence of non-catalytic domains of PARG (the accessory domain
and the additional regulatory domain in mammalian PARGs)
probably limits access to the active site for bulkier ADP-ribosy-
lated protein substrates. It has recently been established that
several macrodomain proteins namely MacroD1, MacroD2 and
TARG1 (refs 16–18) can catalyse the removal of the ﬁnal ADP-
ribose moiety efﬁciently (Fig. 4b). A comparison of the MacroD1
and MacroD2 structures17,21 with the PAR-PARG complex
(Supplementary Fig. S5) reveals that it does not contain the
PARG-speciﬁc catalytic loop insert and associated additional
domains, rendering the MacroD1/D2 active site signiﬁcantly
more accessible to the ADP-ribosylated protein. Furthermore,
unlike for the hydrolysis of the O-glycosidic ribose–ribose
linkage, the formation of the oxocarbenium intermediate in
hydrolysis of the glutamate–ADP-ribose linkage does not require
acid–base catalysis. We propose that MacroD1 and related
proteins catalyse bond breakage by forcing the substrate ribose’
close to the a-phosphate, similar to what has been suggested for
PARG. Although the MacroD1/D2 and PARG structures share
similarities in the binding mode of the ADP-ribose module, the
related non-catalytic MacroH2A.1.1 (ref. 22) has a distinct
conformation for the ribose’, supporting the notion that
enzymatic macrodomains achieve catalysis by inducing
substrate strain. It has been suggested that in MacroD1/D2 a
conserved structural water molecule, positioned between the
ribose and the alpha-phosphate, could be activated by the latter.
In view of the established pKa of a-phosphates ofB2 (ref. 21),
this seems unlikely. In the absence of any obvious MacroD1/
MacroD2-derived acid–base catalyst, it is possible that the Glu
leaving group is involved in assisting hydrolysis of the
oxocarbenium intermediate or that non-enzymatic hydrolysis of
the unstable intermediate occurs.
Discussion
The TTPARG–PAR9 complex crystal structure represents the ﬁrst
visualization of PAR binding at atomic detail and encourages
further structural studies aimed at understanding PAR-protein
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Figure 4 | A mechanism for poly-ADP-ribose hydrolysis. (a) A detailed mechanism for PARG and MacroD1 based on the PARG-PARG structure.
R1¼pADPr for PARG, glutamate for MacroD1 and R2¼ADP. (b) PARG is unable to hydrolyse the terminal ADP-ribose–PARP1 bond. MacroD1 and human
PARG activities on radioactively labelled poly(ADP-ribosyl)ated PARP1. MacroD1 WT and the catalytic mutant, G270E, as well as human PARG E756Q
mutant, are unable to process PAR. (c) MacroD1 WTremoves the terminal ADP-ribose group attached to mono(ADP-ribosyl)ated PARP1 E988Q substrate.
In contrast, the MacroD1 catalytic mutant and human PARG do not exhibit the mono(ADP-ribosyl) hydrolase activity.
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biochemical and modelling studies, the structural data indicate
that canonical PARG is inherently predisposed to act as an exo-
glycohydrolase owing to higher afﬁnity for the PAR terminus, a
consequence of the presence of the conserved phenylalanine
residue (Phe398/902). Unlike the bacterial PARG, however, a
(latent) low-afﬁnity endo-glycohydrolase binding mode is possi-
ble, as conﬁrmed by our LC-MS studies of the WT proteins. This
suggests that, in vivo, the relative balance between exo- and endo-
glycohydrolase activity will be a function of the PAR/PARG ratio.
The latter mode of action is more likely in cases where PAR/
PARG ratio is increased, for instance, when cells encounter
extreme stress leading to excess PAR production and apoptosis,
where released larger oligo-PAR fragments may act to further
amplify the apoptotic signal23. We suggest that under normal
physiological conditions ADP-ribose is the dominant PARG
product, with the latent endo-glycohydrolase activity of PARG
activated by increased PAR/PARG ratios and/or increasing PAR
chain lengths following cellular insult. The ﬁnal step in complete
removal of PAR requires hydrolysis of the glutamate–ADP-ribose
linkage connecting PAR to the modiﬁed protein. This reaction is
catalysed by MacroD family of proteins (in addition to TARG1),
which do not contain the PARG-speciﬁc acid–base catalytic
machinery, but make similar use of substrate strain to catalyse the
formation of the oxocarbenium intermediate.
Methods
Plasmids and proteins. The WT and mutant T. thermophila PARG2
(TTHERM_00294690) were expressed from the pET28a vector (Novagen). Human
PARG with an N-terminal truncation (D1–455) served as a reference for the WT
PARG activity, and the mutant PARG constructs were expressed from the pColdTF
vector (Takara). All proteins bear an N-terminal his-tag. For crystallization studies,
T. thermophila E256Q mutant was puriﬁed by fast protein liquid chromatography
(FPLC) on a HisTrap HP column (GE Healthcare), followed by size-exclusion
chromatography using HiLoad 16/60 Superdex 200 column. Mutations were
introduced using the QuickChange II Site-Directed Mutagenesis kit (Stratagene).
PARG activity assays. For western blot analysis of PARG activity, PAR was
synthesized by the automodiﬁcation of PARP1 in a reaction mixture containing
2 units of PARP1 (Trevigen), 200mM NAD (Trevigen), activated DNA (Trevigen),
50mM Tris (pH 7.5) and 50mM NaCl at room temperature. Reactions were
stopped after 30min by the addition of the PARP inhibitor KU-0058948 and
contain 5mM of PAR. In mutational studies, either 80nM human NTR1 or 7nM
T. thermophila WT and mutant PARGs were added to the reactions and incubated
for another 30min. In PARG inhibition studies, a preincubation step with
T. curvata E115Q (ref. 9) was included. In the latter assays, the reaction mix was
incubated with increasing amounts (0.05, 0.1, 0.5, 0.75, 1, 2, 5 and 10mM) of
T.curvata E115Q PARG for 5min before the addition of 20nM human full-length
or 30nM T. thermophila PARGs, followed by a subsequent 15-min incubation
at room temperature. All reactions were run on 4–12% SDS–PAGE gels and blotted
onto a nitrocellulose membrane. PAR hydrolysis was visualized by rabbit
polyclonal anti-PAR antibodies (Trevigen; 1:1,000 dilution). Western blots were
analysed densitometrically by GeneTools (SynGene), followed by statistical analysis
using a paired t-test.
PAR isolation and analytical veriﬁcation. PAR biosynthesized by tankyrase 1
(1,093–1,327) in the presence of histones were detached with potassium hydroxide
and puriﬁed by means of the dihydroxy boronyl column. The resulting bulk
polymers were fractionated by anion exchange chromatography and desalted to
yield PAR of deﬁned lengths20.
Crystallization and structure solution. A concentration of 15.5mgml 1
TTPARG E256Q was incubated with a series of puriﬁed PAR fragments at 1mM
(hexamer, heptamer, decamer, tetradecamer and pentadecamer were used) before
setting down sitting-drop vapour diffusion trays. Crystals were observed for all
PAR fragments tested under a range of conditions. Crystals were ﬂash-cooled in
liquid nitrogen, and diffraction data were collected at the Diamond Lightsource
(UK), reduced and scaled using X-ray Detector Software (XDS)24. The highest
resolution data were obtained for a PAR9 complex, which was obtained in 0.1M
HEPES, pH 7.0, and 30% v/v Jeffamine ED-2001 at 4C. The structure was solved
by molecular replacement using the WT TTPARG structure10 (PDB ID: 4EPP),
and ﬁnal reﬁnement statistics are given in Table 2.
Molecular dynamics simulations. Topology and parameter ﬁles for the PAR
trimer were obtained using the Antechamber program25 with AM1-BCC charges26.
The PARG–ligand complex model was placed in a periodic water box (TIP3) and
neutralized by adding Naþ ions. This complex was equilibrated with several cycles
of minimizations (steepest descent, 10,000 steps) and MD simulations (50K, 20ps)
with the protein atoms ﬁxed. MD simulations were performed (310K, 0.5ns) at a
time step of 2ps, with the protein backbone restrained to the X-ray structure
conformation. Individual snapshots showing the PARG–ligand interactions were
extracted from the last 100-ps simulation, and minimized (10,000 steps, steepest
descent). The overall r.m.s.d. of the PARendo–PARG model with the X-ray
coordinates was 0.43Å for all Ca atoms.
pKa calculations. Calculations of pKa values were made with a combined Finite
Difference Poisson–Boltzmann and Debye–Hu ¨ckel method, termed FDDH27,28.
Relative dielectric values of 78.4 (water) and 4 (protein, Finite Difference Poisson–
Boltzmann method) were assigned, with an ionic strength of 0.15M. Calculations
were made for TTPARG with and without the bound PAR substrate.
Ultrahigh-performance liquid chromatography coupled to quadrupole time-of-
ﬂight mass spectrometry. The poly(ADP-ribosyl)ated PARP1 was treated with
PARG, and the mixture was ﬁltered using centricons (30kDa cutoff). The analysis
of the ﬁltrate was performed using a modiﬁed procedure by Coulier et al.29,a s
described earlier in Dunstan et al.10 Brieﬂy, all analyses were performed using a
Waters Acquity ultrahigh-performance liquid chromatography system (Waters,
Milford, MA, USA), equipped with a binary solvent delivery system and
autosampler. The chromatographic separations used a column (100mm 2.1mm)
ﬁlled with a 1.7mmB E HC 18 stationary phase (Waters, Milford, MA, USA). Binary
gradients at a ﬂow rate of 0.4mlmin 1 were applied for the elution. The eluent A
was water containing 5mmoll 1 of pentylamine, and the pH value was adjusted to
6.5 using acetic acid, whereas the eluent B was acetonitrile. A fast elution gradient
was applied, starting with 2% B, and then the percentage of B linearly increased to
25% in 5min, followed by an isocratic hold until 10min.
The mass spectrometry was performed on a quadrupole time-of-ﬂight Premier
instrument (Waters Micromass, Manchester, UK) using an orthogonal Z-spray–
electrospray interface. The instrument was operated in V mode, with time-of-ﬂight
mass spectrometry data being collected between m/z 100 and 2,000, applying
collision energy of 4eV. All acquisitions were carried out using an independent
reference spray via the lock spray interface, whereas leucine enkephalin was applied
as a lock mass in negative ionization mode (m/z 554.2615).
Table 2 | Crystallographic data and model reﬁnement
parameters.
TTPARG E256Q-PAR9
Data collection
Space group P212121
Cell dimensions
a, b, c (Å) 55.8, 75.6, 138.7
a, b, g () 90.0, 90.0, 90.0
Resolution (Å) 30 (1.55–1.46)
Rmeas 7.9 (82.5)
I/sI 13.91 (2.11)
Completeness (%) 99.4 (97.7)
Redundancy 5.46
Reﬁnement
Resolution (Å) 30–1.46
No. of reﬂections 103,366
Rwork/Rfree 13.8/17.7 (24.2/28.9)
No atoms
Protein 7,392
Ligand 92
Water 386
B-factors (Å2)
Protein 14.7
Ligand 16.6
Water 27.0
R.m.s. deviations
Bond lengths (Å) 0.026
Bond angles () 2.067
Values in parentheses indicate values obtained for the highest resolution shell.
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& 2013 Macmillan Publishers Limited. All rights reserved.The reaction products, expected to occur in the reaction mixture, in particular
ADP-ribose and oligomers of poly-ADP-ribose with up to ﬁve ADP-ribose units, as
well as NADþ, were searched for using extracted ion chromatograms. The target
analyses were based on the characteristic accurate m/z ratios applying a mass
window of 50mDa. As the information on the electrospray ionization mass spectra
for oligomeric ADP-ribose species are only scarcely available in the literature30, the
recorded total ion current (TIC) chromatograms were systematically examined
using speciﬁc masses of possible mono- and multiply charged ions of individual
oligomers. The optimal responses were obtained using m/z ratios of 558.0639,
1,099.125, 819.589 and 1,090.120 for deprotonated ADP-ribose, deprotonated
ADPR dimer, doubly charged deprotonated ADPR trimer and doubly charged
deprotonated ADPR tetramer, respectively. The relative contributions of the
individual oligomers were determined assuming that they had the same responses
as ADPR.
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